INVESTORS

AT A GLANCE

"A pioneer of digital therapeutics, Voluntis was the first such company to go public. Personally, and in the name of the entire Voluntis team, I would like to thank all of our new and historic shareholders for their faith in us. This investment of €30.1M will allow us to continue our commitment to patients and healthcare professionals, helping them better manage treatment in the hopes that this improves real-world efficacy." - Pierre Leurent, CEO of Voluntis

STOCK INFORMATION

EURONEXT Paris

WHAT'S NEW

Upcoming events

29 June 2020

Annual General Assembly

SURESNES

29 Sept. 2020

Publication of H1 2020 results

CONFERENCE CALL

2019 Annual Results

NEWS

Voluntis and Bristol-Myers Squibb to co-develop digital therapeutics for oncology

PRESS RELEASES

DOCUMENTS

No documents match your search. Please choose different criteria.

CONTACT THE INVESTOR RELATIONS TEAM

NewCap
Louis-Victor Delouvrier
21, place de la Madeleine
75008 Paris, France
Tel: +33 (0)1 44 71 94 94
Email: voluntis@newcap.eu